CD22

Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct

Retrieved on: 
Tuesday, January 11, 2022 - 11:00am

SEATTLE, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company entered into an agreement with the National Cancer Institution (NCI), an institute of the National Institutes of Health (NIH), for worldwide exclusive commercial rights to the NIH’s CD22 chimeric antigen receptor (CAR) with a fully-human binder for use in certain in vivo gene therapy and ex vivo allogeneic CAR T applications for B cell malignancies.

Key Points: 
  • Engineered CAR T cell therapies for B cell malignancies use binders to target proteins expressed on the surface of B cells.
  • Unfortunately, incomplete responses or relapses occur in over 50% of CD19 CAR T-treated patients, often due to CD19 antigen loss.
  • CD22, which is also a B cell surface protein, has emerged as an alternative to address failure to achieve durable complete responses with CD19-directed CAR T therapy.
  • We are thrilled to enter an agreement with the NIH for an exclusive license to this fully-human CD22 CAR, particularly given the clinical data with this specific construct to date.

SinoMab Awared the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong an

Retrieved on: 
Tuesday, January 11, 2022 - 7:55am

The Company was also previously awarded the "Listed Company with Most Growth Potential" in the selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies".

Key Points: 
  • The Company was also previously awarded the "Listed Company with Most Growth Potential" in the selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies".
  • In addition, SN1011, a key product of the Company, completed its phase I last subject last visit in China in July last year.
  • That reflects the capital market's recognition of the value, management and growth potential of the Company and is a great encouragement to the Company.
  • The selection of the "6th Hong Kong Golden Stocks Awards" was jointly organized by Zhitongcaijing.com, a leading Hong Kong and US stock information platform in China, with RoyalFlush Finance and China Galaxy Securities.

Autolus Therapeutics announces 2022 priorities

Retrieved on: 
Monday, January 10, 2022 - 12:00pm

LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its 2022 corporate priorities and provided guidance.

Key Points: 
  • LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its 2022 corporate priorities and provided guidance.
  • We are very excited about the year ahead, which could be a transformational year for Autolus.
  • Updates on the FELIX trial, where Autolus is evaluating obe-cel in r/r adult ALL patients.
  • In July 2021, Autolus announced its entry into an agreement with Moderna, Inc., granting Moderna an exclusive license to develop and commercialize mRNA-based therapeutics incorporating Autolus proprietary binders for up to four immuno-oncology targets.

Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation

Retrieved on: 
Tuesday, January 4, 2022 - 9:30pm

This focus allows us to extend our cash runway (excluding our subsidiary Calyxt, Inc.) into early 2024.

Key Points: 
  • This focus allows us to extend our cash runway (excluding our subsidiary Calyxt, Inc.) into early 2024.
  • Cellectis targets to enroll patients at Dose Level 2 (DL2) and eventually escalate to higher dose levels with FCA preconditioning regimen.
  • Cellectis targets to enroll patients at Dose Level 1 (DL1) with Fludarabine and Cyclophosphamide (FC) preconditioning regimen.
  • Cellectis targets to file an IND for UCART20x22 and to initiate a Phase 1 trial in 2022.

Aberrant Splicing of CD22 in Acute Lymphoblastic Leukemia Underlies Resistance to Immunotherapy

Retrieved on: 
Tuesday, January 4, 2022 - 3:44pm

One way to achieve this is by paying close attention to aberrant RNA splicing events, like those described in our study."

Key Points: 
  • One way to achieve this is by paying close attention to aberrant RNA splicing events, like those described in our study."
  • Adoptive immunotherapy, in which a patient's own immune system is used to kill cancer cells, has been a breakthrough in the treatment of B-ALL.
  • Although earlier studies had shown that CD22 undergoes alternative splicing, the role of these CD22 isoforms in the context of immunotherapy had not been characterized.
  • In one case, it was the only CD22 isoform, and predictably that patient did not respond to treatment with inotuzumab.

Arix Bioscience PLC: Autolus Therapeutics presents positive obe-cel data at the American Society of Hematology (ASH) Annual Meeting 2021

Retrieved on: 
Monday, December 20, 2021 - 11:42am

As of the cut-off date of 13 September, 16 patients in the Phase 1b part of the FELIX study had received obe-cel.

Key Points: 
  • As of the cut-off date of 13 September, 16 patients in the Phase 1b part of the FELIX study had received obe-cel.
  • Patient characteristics in the FELIX 1b portion were broadly comparable to those observed in the ALLCAR19 study in r/r adult B-ALL.
  • The company expects to present data from the Phase 2 portion of the FELIX study in 2022.
  • To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus' website.

Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition

Retrieved on: 
Monday, December 13, 2021 - 12:00pm

LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, presented further progress on obecabtagene autoleucel (obe-cel) in an oral presentation [Abstract 477] entitled “Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process” at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021. The Company also presented an update of obe-cel in relapsed/refractory aggressive and indolent B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL) patients from the ALLCAR19 extension study, as well as preclinical and initial engraftment data with AUTO1/22 in Pediatric ALL in two separate poster presentations [Abstracts 3823 and 1710, respectively].

Key Points: 
  • Patient characteristics in the FELIX 1b portion were broadly comparable to those observed in the ALLCAR19 study in r/r adult B-ALL.
  • 75% patients in the FELIX Phase 1b had >20% blasts at pre-conditioning, compared with 60% patients in ALLCAR19.
  • The company expects to present data from the Phase 2 portion of the FELIX study in 2022.
  • In collaboration with Autolus academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trials for B-NHL.

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

Retrieved on: 
Tuesday, November 30, 2021 - 11:50am

The patients currently in screening will be randomized by end of December 2021, given eligibility criteria are met.

Key Points: 
  • The patients currently in screening will be randomized by end of December 2021, given eligibility criteria are met.
  • SM03 (Suciraslimab), a potential global first-in-target anti-CD22 monoclonal antibody for the treatment of RA and potentially for the treatment of other immunological diseases, is currently in Phase III clinical trials in China.
  • The Phase III clinical trial is a multi-center, randomized, double-blind, placebo-controlled, parallel group study to confirm the clinical efficacy and long-term safety in active RA patients receiving methotrexate (MTX).
  • The efficacy and safety of Suciraslimab was previously evaluated in a phase II clinical study in moderate-to-severely active RA patients.

SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health

Retrieved on: 
Friday, November 26, 2021 - 9:26am

With the theme of "Shaping a Resilient and Sustainable Future", the Inaugural ASGH was held at the Convention Hall of Hong Kong Convention and Exhibition Centre and synchronized online.

Key Points: 
  • With the theme of "Shaping a Resilient and Sustainable Future", the Inaugural ASGH was held at the Convention Hall of Hong Kong Convention and Exhibition Centre and synchronized online.
  • Doing innovative research in Hong Kong enjoys advantages such as legal protection and patenting system, which will facilitate the companies to get licensed with other collaborators.
  • Dr. Shui On LEUNG said, "It is a great honour to attend the Inaugural ASGH on behalf of the Company.
  • SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases.

CAR-T Therapy Pipeline Analysis Report 2021 - Global Market Opportunities and Strategies to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 29, 2021 - 9:59am

The "CAR-T Therapy Pipeline Analysis Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CAR-T Therapy Pipeline Analysis Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • The global CAR-T therapy market reached a value of nearly $1,037 million in 2020.
  • North America was the largest region in the global CAR-T therapy market, accounting for 56.1% of the total in 2020.
  • Player-adopted strategies in the CAR-T therapy market include expansion through mergers and acquisitions, and strategic partnerships with technology companies.